CRISPR Therapeutics will debut first-in-human Phase 1 data for its in vivo CRISPR/Cas9 therapy CTX310, which targets ANGPTL3 for cardiometabolic disease, in a late-breaking oral at AHA 2025. The company also secured a late-breaking basic science poster for CTX340, a preclinical angiotensinogen (AGT) editing program for refractory hypertension. The data remain embargoed until presentation.
The immediate news is positioning: after establishing clinical and regulatory credibility with an ex vivo program in hemoglobinopathies, CRISPR is moving aggressively into common cardiovascular disease with a liver-directed LNP platform. CTX310 is already in clinical trials across heterozygous and homozygous familial hypercholesterolemia, mixed dyslipidemias, and severe hypertriglyceridemia, while a parallel Lp(a) program (CTX320) is also in clinical trials. ANGPTL3 is a known lever for triglycerides, non-HDL cholesterol, and LDL-C; AGT is a central node in the renin–angiotensin system. The company is effectively staking a claim that one-time editing can compete with, or surpass, chronic biologics and RNAi that have established efficacy but depend on repeated dosing.
Strategically, this reads as an expansion play into a competitive but still unclaimed space for durable genetic medicines in cardiometabolic disease. The target choices are intentional. ANGPTL3 provides a path into phenotypes where PCSK9 pathways underperform and where evinacumab has already validated biology, setting a high bar on lipid lowering and safety. AGT squarely challenges the emerging RNAi class in hypertension by trading reversibility for durability—an advantage for adherence but a potential liability in a disease where titration and reversal remain core to risk management. The AHA late-breaking slot suggests CRISPR expects a credible biomarker signal from CTX310; the real strategic question is whether safety and edit durability are compelling enough to justify one-time intervention in largely preventive populations.
For clinical operations, this marks a further shift of genome editing from rare, high-acuity settings into high-prevalence indications that demand different infrastructure and oversight. Sites will need lipid and blood pressure phenotyping at scale, intensive early safety monitoring for infusion and immunogenicity risks, and long-term follow-up typical of genome editing studies. Central lab capacity for standardized lipid panels, ANGPTL3 protein assays, and sensitive hepatotoxicity monitoring will be gating. CROs should anticipate extended pharmacovigilance and outcomes tracking, as well as the incorporation of genomic off-target analyses into routine data packages. For hypertension, protocol design must reconcile a one-and-done mechanism with rescue therapy plans, ambulatory BP monitoring, and drug–drug interaction management with RAAS agents—an area already under scrutiny in the RNAi class.
Regulatory and market dynamics will shape the trajectory. In dyslipidemia, robust and durable LDL-C and triglyceride lowering with a manageable transaminase profile and clean off-target assessment could be enough to advance to dose expansion, with outcomes requirements likely deferred but not avoided. In hypertension, regulators will be cautious about irreversible RAAS modulation, particularly in patients with comorbid CKD or variable volume status. Payers will press on patient selection, durability, and the economics of one-time therapies versus branded chronic agents; real-world adherence advantages must be weighed against irreversible exposure.
What to watch at AHA: magnitude and durability of lipid reductions for CTX310, dose–response, on-target editing markers, transaminase and inflammatory signals, and any complement or infusion-related events. For CTX340, preclinical BP reduction with safety margins relative to existing RAAS blockers and RNAi comparators will set expectations for translation. Near-term, clarity on Phase 2 planning, long-term follow-up architecture, and manufacturing scale for LNP–Cas9 will be determinative. The unresolved tension is whether the field—and regulators—are ready to accept permanent edits for conditions traditionally managed by titratable, reversible therapies.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
